epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLCepilepsia-100Research ArticleCLINICAL LECTURESКЛИНИЧЕСКИЕ ЛЕКЦИИЭФФЕКТИВНОСТЬ И ПЕРЕНОСИМОСТЬ ПЕРАМПАНЕЛА У ПОДРОСТКОВ И ВЗРОСЛЫХ С РЕЗИСТЕНТНОЙ ФОКАЛЬНОЙ ЭПИЛЕПСИЕЙ. ОБЗОР ДАННЫХ МЕЖДУНАРОДНЫХ ИССЛЕДОВАНИЙБелоусоваЕ. Д.Научно-исследовательский клинический институт педиатрии имени академика Ю.Е. Вельтищева Российского национального исследовательского медицинского университета имени Н.И. Пирогова, МоскваRussian Federation20140606201665Special issue69Copyright © Белоусова Е.Д., 20162016Белоусова Е.Д.Белоусова Е.Д.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/100
.
ReferencesKwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia. 2001; 42 (10): 1255-60.Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia. 2001; 42 (10): 1255-60.Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008; 70 (1): 54-65.Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008; 70 (1): 54-65.Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents. 2011; 11: 56-63.Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents. 2011; 11: 56-63.Hanada T. et al. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011; 52: 1331-40.Hanada T. et al. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011; 52: 1331-40.French J.A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.French J.A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial- onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial- onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.Krauss G.L. et al. Randomized phase III study 306: adjunctive perampanel for partial onset seizures. Neurology. 2012; 78: 1408-15.Krauss G.L. et al. Randomized phase III study 306: adjunctive perampanel for partial onset seizures. Neurology. 2012; 78: 1408-15.Steinhoff B.J. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-9.Steinhoff B.J. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-9.Krauss G.L. et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307. Epilepsia. 2013; 54: 126.Krauss G.L. et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307. Epilepsia. 2013; 54: 126.
The authors declare that there are no conflicts of interest present.